The importance of resilience for treatment adhesion in patients with systemic lupus erythematosus

Daniella Antunes Pousa Faria, Luciana Silva Revoredo, Maria José Pereira Vilar, Eulália Maria Chaves Maia
DOI: 10.15305/ijrci/v3i1/118

Abstract

Resilience (RS) is a component of the psychological structure that helps in the process of tackling adverse situations such as catastrophes, traumas, and diseases. It has been described in the literature as an important psychological aspect that might assist patients with chronic diseases to cope with the disease process, thereby to better adapt to the dynamic complex of the disease, including changes in routines, acceptance of the disease and its limitations, and also to increase treatment adhesion. The objective of this study is to conduct a literature review on the general concepts of RS and to synthesize the knowledge gained through research on the contributions of RS to treatment adherence in patients with systemic lupus erythematosus (SLE). The research results have shown that the study of RS in patients with SLE is very recent and it could contribute to increase the coping skills, treatment adherence, and develop a positive mental attitude in patients, thereby to avoid risks and promote protection factors


Citation

Faria DAP, Revoredo LS, Vilar MJP, Maia EMC. IJRCI. 2015;3(1):R1 (9 March 2015) DOI: 10.15305/ijrci/v3i1/118

Keywords

Resilience; Systemic Lupus Erythematosus; Chronic Diseases.

References

1. Beccastrini E, D’Elios MM, Emmi G, Silvestri E, Squatrito D, Prisco D, et al. Systemic lupus erythematosus: immunopathogenesis and novel therapeutic targets. Int J Immunopathol Pharmacol. 2013; 26(3):585-96.

2. Costa-Reis P, Sullivan KE. Genetics and epigenetics of systemic lupus erythematosus. Curr Rheumatol Rep. 2013; 15(9):369.

3. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010; 39(4):257-68.

4. Sauma MFLC, Nunes NAC,Lopes LFM. Estudo retrospectivo das manifestações mlínicas e laboratoriais de 104 pacientes com Lúpus Eritematoso Sistêmico (LES), em Belém, PA, Brasil (1990-1999). Rev. Bras. Reumatol. 2004; 44(3):192-197.

5. Bezerra ELM, Vilar MJP, Barbosa OFC, Santos SQ, Castro MA, Trindade MC, et al. Systemic lupus erythematosus (SLE): clinical and laboratory profile of patients followed at the Onofre Lopes University Hospital (UFRN - Natal/Brazil) and early organ damage in patients with recently diagnosed disease. Rev. Bras. Reumatol. 2005; 45(6): 339-342.

6. Sato EI, Bonfá ED, Costallat LTL, Silva NA, Brenol JCT, Santiago MB, et al. Lúpus eritematoso sistêmico: acometimento cutâneo/articular. Rev. Assoc. Med. Bras. 2006; 52(6):384-386.

7. D’Cruz DP, Khamashta MA, Hughes GR. Systemic Lúpus erythematosus. Lancet. 2007; 369(9561): 587-96.

8. Freire EA, Maia IO, Nepomuceno JC, Ciconelli RM. Damage index assessment and quality of life in systemic lupus erythematosus patients (with long-term disease) in Northeastern Brazil. Clin Rheumatol. 2007; 26(3):423-8.

9. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8):2677-86.

10. Gurevitz SL, Snyder JA, Wessel EK, Frey J, Williamson BA. Systemic lupus erythematosus: a review of the disease and treatment options. Consult Pharm. 2013; 28(2):110-21.

11. Borba EF, Latorre LC, Brenol JCT, Kayser C, Silva NA, Zimmermann AF, et al. Consenso de Lúpus Eritematoso Sistêmico. Rev Bras Reumatol. 2008; 48(4): 196-207.

12. Ayan C, Martin V. Systemic Lúpus erythematosus and exercise. Lupus. 2007; 16(1): 5-9.

13. Leong KP, Kong KO, Thong BY, Koh ET, Lian TY, Teh CL, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology (Oxford). 2005; 44(10):1267-76.

14. Sweet JJ, Doninger NA, Zee PC, Wagner LI. Factors influencing cognitive function, sleep, and quality of life in individuals with systemic lupus erythematosus: a review of the literature. Clin Neuropsychol. 2004; 18(1):132-147.

15. Huang HC, Chou CT, Lin KC, Chao YF. The relationships between disability level, health-promoting lifestyle, and quality of life in outpatients with systemic lupus erythematosus. J Nurs Res. 2007; 15(1): 21-32.

16. Doria A, Rinaldi S, Ermani M, Salaffi F, Iaccarino L, Ghirardello A, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford). 2004; 43(12):1580-6.

17. Edworthy SM, Dobkin PL, et al. Group psychotherapy reduces illness intrusiveness in systemic lupus erythematosus. J Rheumatol 2003; 30(5):1011-6

18. Araújo AD, Traverso-Yépez MA. Expressões e sentidos do lúpus eritematoso sistêmico (LES). Estud. psicol. (Natal). 2007; 12(2):119-127.

19. Faria DAP, Revoredo LS, Vilar MJ, Maia EMC. Resilience and Treatment Adhesion in Patients with Systemic Lupus Erythematosus. The Open Rheumatol J. 2014; 8: 1-8.

20. Baker K and Pope J. Employment and work disability in systemic lupus erythematosus: a systematic review. Rheumatology. 2009; 48 (3):281–4.

21. Robinson D, Aguilar D JR, schoenwetter M, et al. Impact of Systemic Lupus Erythematosus on Health, Family, and Work: The Patient Perspective. Arthritis Care Res. 2010; 62 (2):266–73.

22. Carvalho FT, Morais NA, Koller SH, et al. Fatores de proteção relacionados à promoção de RS em pessoas que vivem com HIV/AIDS. Cad Saúde Pública. 2007; 23 (9):2023-33.

23. Ferreira CL, Santos LMO, Maia EMC. RS em idosos atendidos na rede de atenção básica de saúde em município do nordeste brasileiro. Rev Esc Enferm USP. 2012; 46 (2):328-34.

24. Poletto M, Koller SH. Contextos ecológicos: promotores de RS, fatores de risco e de proteção. Estud psicol (Campinas). 2008; 25(3): 405-16.

25. Yunes MAM. Psicologia positiva e RS: o foco no indivíduo e na família. Psicologia em Estudo. 2003; 8:75-84.

26. Ralha-Simões H. RS e desenvolvimento pessoal. In J. Tavares (Org.), RS e educação. 2001, SãoPaulo: Cortez.

27. Herrman H, Stewart DE, Diaz-Granados N. What is resilience?. La Revue canadienne de psychiatrie. 2011; 56 (5):258-265.

28. Laranjeira CASJ. Do Vulnerável Ser ao Resiliente Envelhecer: Revisão de Literatura.Teor. e Pesq. 2007; 23(3):327-332.

29. Carvalho FT, Morais NA, Koller SH, et al. Fatores de proteção relacionados à promoção de RS em pessoas que vivem com HIV/AIDS. Cad Saúde Pública. 2007; 23 (9):2023-33.

30. Tavares BC, Barreto FA, Lodetti M L, Silva DMGV, Lessmann JC. RS de pessoas com Diabetes Mellitus. Texto contexto enferm. 2011; 20(4): 751-757

31. Strand EB, Zautra AJ, Thoresen M, et al. Positive affect as a factor of resilience in the pain—negative affect relationship in patients with rheumatoid arthritis. Journal of Psychosomatic Research. 2006; 60: 477– 484

32. Cal SF, Santiago MB. Resilience in systemic lupus erythematosus. Psychol Health Med 2013; 18(5): 558-63.

33. Quiceno JM, Alpi SV. Resiliencia y características sociodemográficas en enfermos crónicos. psicología desde el caribe. 2012; 29(1): 114-174.

34. Pesce RP, Assis SG, Avanci JQ, Santos NC, Malaquias JV, Carvalhaes R. Adaptação transcultural, confiabilidade e validade da escala de RS. Cad Saúde Pública. 2005;21(2):436-48.

35. Pinheiro, DPM. A RS em discussão. Psicologia em Estudo. 2004; 9(1): 67-75.

36. Bianchini DCS, Dell’Aglio DD. Processos de RS no contexto de hospitalização: um estudo de caso. Paidéia; 16(35): 427-436.

37. Sutanto B, Singh-Grewal D, McNeil HP. et al. Experiences and Perspectives of Adults Living With Systemic Lupus Erythematosus: Thematic Synthesis of Qualitative Studies. Arthritis Care Res 2013; 65(11): 1752-65.

38. Achaval S, Suarez-Almazor ME. Treatment adhesion to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumtol 2010; 5(3): 313–326.

39. World Health Organization (WHO). Adhesion to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.

40. Julian LJ, Yelin E, Yazdany J, et al. Depression, medication adhesion, and service utilization in systemic lupus erythematosus. Arthritis Rheuma. 2009; 61(2): 240-6.

41. Bennett JK, Fuertes JN, Keitel M, Phillips R. The role of patient attachment and working alliance on patient adhesion, satisfaction, and health-related quality of life in lupus treatment. Patient Education and Counseling 2011; 85:53–59.

42. Wagnild GM, Collins JA. Assessing resilience. J Psychosoc Nurs Ment Health Serv. 2009; 47(12): 28-33.

43. Aberer E. Epidemiologic, socioeconomic and psychosocial aspects in lupus erythematosus. Lupus 2010; 19(9): 1118-24.

44. Reis MG, Costa IP. Qualidade de vida relacionada à saúde em pacientes com lúpus eritematoso sistêmico no Centro-Oeste do Brasil. Rev Bras Reumatol . 2010; 50(4): 408-22.

45. Baker K, Pope J, Fortin P, Silverman E, Peschken C. Work disability in systemic lupus erythematosus is prevalent and associated with socio-demographic and disease related factors. Lupus 2009; 18(14): 1281-8.

46. White-Koning M, Bertozzi-Salamon AI, Vignes M, Arnold C. Compliance to treatment of adolescents with cancer. Bull Cancer.2007; 94(4): 349-56.

47. Rodrigues FS, Polidori MM. Enfrentamento e RS de Pacientes em Tratamento Quimioterápico e seus Familiares. Rev Bras Cancerologia. 2012; 58(4): 619-627.